Translation: It’s a competitive business
A new in vitro system called Rec-Seq sheds light on how mRNA molecules compete for the machinery that translates their genetic sequence into proteins.
- Department of Molecular and Cellular Biology, College of Biological Sciences, University of California, Davis, United States
Cells respond to changes in their environment – such as stress, pathogens and growth signals – by altering the proteins they make. The last stage of producing a protein involves a ribosome reading a molecule of mRNA and translating its genetic code into a string of amino acids. However, translating the wrong mRNA at the wrong time can lead to diseases such as cancer or mental illness. Moreover, it is still not fully understood how a ribosome ‘knows’ which mRNA to translate.
For translation to begin, two things need to happen: (i) the correct mRNA strand needs to be recruited to a ribosome; and (ii) the ribosome needs to know where along the mRNA strand it should begin translating. These decisions are highly regulated and depend on the genetic sequence of each mRNA and the availability and activity of proteins called initiation factors (Merrick and Pavitt, 2018).
To better understand how translation is regulated, biochemists have built purified reconstituted systems which recreate translation in vitro using individual components purified from cells (Pisarev et al., 2007). While these systems allow researchers to study translation independently from other mechanisms required for protein production, they can only analyze one mRNA at a time. This is a significant problem because thousands of different mRNAs can be present in a cell, and they compete with each other for a limited number of initiation factors and ribosomes. Now, in eLife, Jon Lorsch, Alan Hinnebusch and colleagues from the National Institutes of Health – including Fujin Zhou as first author – report a new purified reconstituted system made with components from yeast (Saccharomyces cerevisiae) which can incorporate all mRNAs of a cell (Zhou et al., 2024).
The team combined its purified reconstituted system with a deep sequencing method known as Ribo-Seq, which provides a global snapshot of where translating ribosomes are precisely positioned on all mRNAs in a cell (Ingolia et al., 2013). This approach, named Rec-Seq, means that a purified reconstituted system can now be used to study how individual components regulate which mRNAs are recruited to ribosomes and the location of the start site for translation (Figure 1).
Figure 1
How Rec-Seq compares to classic purified reconstituted systems.
In classic reconstituted assays (left), components involved in translation – such as ribosomes and initiation factors – are purified from cells and combined with a single molecule of mRNA (yellow rectangular box indicates the start site of translation). Translation is then initiated in vitro to see how these components, such as the enzyme Ded1 (red triangle), impact the readout produced from the mRNA strand. Zhou et al. have expanded this approach to create a new purified reconstituted system called Rec-Seq that can interact with all mRNAs extracted from a cell (right), mimicking the cellular environment where thousands of different mRNAs compete for a limited number of ribosomes and initiation factors. Deep sequencing is then applied to the mRNA molecules, which have been broken down by the enzyme RNase, to reveal how individual components like Ded1 impact translation. For instance, which mRNA strands are translated more (green up arrow), less (red down arrow), or are unaffected (black bar) when Ded1 is present, and how Ded1 impacts the start site where ribosomes begin translating from.
Previous in vivo experiments on yeast cells using the Ribo-Seq method found that the helicase enzyme Ded1 (known as DDX3X in humans) promotes recruitment to the ribosome and determines where translation will be initiated for over 600 mRNAs (Sen et al., 2015). However, Ded1 is involved in many other RNA processes, including the formation of ribosomes, stress granules, and P-bodies (Sharma and Jankowsky, 2014). Ded1-dependent changes in these processes may affect translation, making it difficult to interpret whether Ded1 directly or indirectly regulates translation. Moreover, changing the amount of any component involved in translation could down-regulate (or up-regulate) the level of other proteins that may impact this process.
Lorsch and co-workers have previously shown that the Ded1 helicase enzyme has a direct role in promoting the translation initiation of a handful of the mRNAs identified by Ribo-Seq (Gupta et al., 2018). However, their new Rec-Seq system revealed over 1,000 mRNAs require Ded1 to be efficiently recruited to ribosomes when all mRNAs are present and competing with one another. Consistent with Ribo-Seq data, the untranslated end of these mRNAs was relatively long and highly structured. This suggests that Ded1 has a role in unwinding mRNA molecules to promote their recruitment to ribosomes and to expose their start site for translation.
Zhou et al. also varied the amount of another helicase enzyme, eIF4A. Rec-Seq analysis showed that essentially all mRNAs required this enzyme to be recruited to ribosomes regardless of the structural complexity of their untranslated end, consistent with previous findings (Yourik et al., 2017). Together, this work highlights that the helicase enzymes Ded1 and elF4A have distinct regulatory roles in translation.
In the future, it will be interesting to add more complexity to the Rec-Seq system so that it can capture other regulatory processes, such as the regulation of translation by upstream open reading frames or the role of other proteins that bind to specific mRNAs. The method could also be calibrated using available Ribo-Seq data to remove potential artifacts and biases that are inherent to reconstituted systems.
Nevertheless, the current Rec-Seq approach developed by Zhou et al. provides an excellent purified reconstituted system for studying what happens during translation when all the mRNAs of a cell are able to compete for ribosomes. This breakthrough will allow scientists to better understand how translation works in a ‘typical’ cellular environment. It may also lead to the discovery of delicate, yet physiologically important, regulatory mechanisms that cannot be readily detected using traditional reconstituted systems.
References
-
Genome-wide annotation and quantitation of translation by ribosome profilingCurrent Protocols in Molecular Biology 103:mb0418s103.https://doi.org/10.1002/0471142727.mb0418s103
-
Protein synthesis initiation in eukaryotic cellsCold Spring Harbor Perspectives in Biology 10:a033092.https://doi.org/10.1101/cshperspect.a033092
-
Assembly and analysis of eukaryotic translation initiation complexesMethods in Enzymology 430:147–177.https://doi.org/10.1016/S0076-6879(07)30007-4
-
The Ded1/DDX3 subfamily of DEAD-box RNA helicasesCritical Reviews in Biochemistry and Molecular Biology 49:343–360.https://doi.org/10.3109/10409238.2014.931339
Article and author information
Author details
Christopher S Fraser
Publication history
Copyright
© 2024, Sokabe and Fraser
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 419
- views
-
- 27
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Translation: It’s a competitive business
eLife 13:e96304.
https://doi.org/10.7554/eLife.96304
Further reading
-
- Chromosomes and Gene Expression
- Structural Biology and Molecular Biophysics
Type II nuclear receptors (T2NRs) require heterodimerization with a common partner, the retinoid X receptor (RXR), to bind cognate DNA recognition sites in chromatin. Based on previous biochemical and overexpression studies, binding of T2NRs to chromatin is proposed to be regulated by competition for a limiting pool of the core RXR subunit. However, this mechanism has not yet been tested for endogenous proteins in live cells. Using single-molecule tracking (SMT) and proximity-assisted photoactivation (PAPA), we monitored interactions between endogenously tagged RXR and retinoic acid receptor (RAR) in live cells. Unexpectedly, we find that higher expression of RAR, but not RXR, increases heterodimerization and chromatin binding in U2OS cells. This surprising finding indicates the limiting factor is not RXR but likely its cadre of obligate dimer binding partners. SMT and PAPA thus provide a direct way to probe which components are functionally limiting within a complex TF interaction network providing new insights into mechanisms of gene regulation in vivo with implications for drug development targeting nuclear receptors.
-
- Cancer Biology
- Chromosomes and Gene Expression
Telomeres are crucial for cancer progression. Immune signalling in the tumour microenvironment has been shown to be very important in cancer prognosis. However, the mechanisms by which telomeres might affect tumour immune response remain poorly understood. Here, we observed that interleukin-1 signalling is telomere-length dependent in cancer cells. Mechanistically, non-telomeric TRF2 (telomeric repeat binding factor 2) binding at the IL-1-receptor type-1 (IL1R1) promoter was found to be affected by telomere length. Enhanced TRF2 binding at the IL1R1 promoter in cells with short telomeres directly recruited the histone-acetyl-transferase (HAT) p300, and consequent H3K27 acetylation activated IL1R1. This altered NF-kappa B signalling and affected downstream cytokines like IL6, IL8, and TNF. Further, IL1R1 expression was telomere-sensitive in triple-negative breast cancer (TNBC) clinical samples. Infiltration of tumour-associated macrophages (TAM) was also sensitive to the length of tumour cell telomeres and highly correlated with IL1R1 expression. The use of both IL1 Receptor antagonist (IL1RA) and IL1R1 targeting ligands could abrogate M2 macrophage infiltration in TNBC tumour organoids. In summary, using TNBC cancer tissue (>90 patients), tumour-derived organoids, cancer cells, and xenograft tumours with either long or short telomeres, we uncovered a heretofore undeciphered function of telomeres in modulating IL1 signalling and tumour immunity.
